Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Asthma

Treatments: Other: HFA-134a; Other: Radiolabeled saline solution; Other: HFA-152a

Study type: Interventional

Funder types: Industry

Identifiers

NCT06506266

221781

Details and patient eligibility

About

The main goal of the study is to assess the effect of the administration of reference propellant [HFA-134a (1,1,1,2 - Tetrafluoroethane)] and test propellant [HFA-152a (1 - Difluoroethane)] in healthy adults on mucociliary clearance (MCC).

Enrollment: 24 patients

Sex: All

Ages: 30 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Participants are eligible to be included in the study only if all following criteria apply:

• Male or Female, age 30 to 55 years

• Body Mass Index (BMI): 18.0 to 32.0 kg/m2, inclusive, at screening

• Weight: ≥50 kg

• Nonsmokers or ex-smokers for more than 6 months with a smoking history of <10 pack years

• Status: healthy participants

• Spirometry data.

  • Forced Expiratory Volume in 1 second (FEV1) ≥80% of predicted values.
  • FEV1: Forced vital capacity (FVC) ratio >70%.

• Females must be of nonchildbearing potential, and agree not to donate eggs (ova, oocytes) for the purpose of reproduction during the study intervention period and at least 30 days after the last dose of study intervention.

• Male participants are eligible to participate if they agree to:

  • Refrain from donating sperm
  • Either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
  • Or must agree to use a male condom when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. The female partner should additionally use a highly effective contraceptive method with a failure rate of <1% per year.

• All prescribed medication must have been stopped at least 30 days prior to admission to the clinical research centre based on investigator judgment. An exception is made for Hormonal Replacement Therapy (HRT), and occasional paracetamol which may be used throughout the study.

• Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

• Capable of using inhaler device with no physical or other issues which would impair the participant's ability to successfully use a metered dose inhaler (MDI) inhaler as instructed in this study.

• Ability to comply with the protocol. Participants have capacity and no issues which would impair their ability to comply with all aspects of the protocol during the study

Exclusion criteria

Participants who meet any of the following exclusion criteria at screening will not be eligible to participate in the study:

• Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker shall participate in the study.
• History or presence of any form of asthma, including childhood asthma and exercise induced asthma.
• Respiratory disorders other than asthma. A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, Chronic obstructive pulmonary disease (COPD), tuberculosis, known alpha 1 antitrypsin deficiency and other respiratory abnormalities other than asthma that, in the opinion of the investigator, could put the participant at risk through study participation or could affect the study analyses and data interpretation.
• Recent history of mild conditions potentially affecting Mucociliary clearance (MCC) (viral infections, cough, cold, active hay fever etc.) in the last 14 days.
• Recent use of drugs for treating conditions potentially affecting MCC (viral infections, cough, cold, etc.) in the last 30 days.
• Vaccine(s) within 2 weeks prior to admission or plans to receive such vaccines during the study.
• Current enrolment or past participation in this clinical study.
• Positive human immunodeficiency virus (HIV) antibody test.
• Regular use of known drugs of abuse, including Tetrahydrocannabinol (THC).
• Average intake of more than 21 units of alcohol per week in males and 14 units per week in females (clinical site standard: unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits) based on breath alcohol test.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

24 participants in 2 patient groups

HFA-152a followed by HFA-134a

Experimental group

Treatment:

Other: HFA-152a

Other: Radiolabeled saline solution

Other: HFA-134a

HFA-134a followed by HFA-152a

Experimental group

Treatment:

Other: HFA-152a

Other: Radiolabeled saline solution

Other: HFA-134a